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 Objectives To assess the prevalence of allergic rhinitis in adult patients with 
asthma in Hong Kong, and to compare the morbidity endured by 
asthma patients with and without allergic rhinitis.
 Design Cross-sectional study.
 Setting Respiratory clinics of four major public hospitals in Hong Kong.
 Patients A total of 600 adults with asthma were recruited from March to 
May 2007. 
 Main outcome measures Doctors and patients completed separate questionnaires 
evaluating symptoms, treatment, and health care utilisation. 
Spirometry data were obtained for a subgroup of patients at the 
time of survey completion.
 Results The patients consisted of 267 males and 333 females, with 251 
having spirometry data. The mean pre-bronchodilator 1-second 
forced expiratory volume predicted among those who had 
spirometry performed was 88% (standard deviation, 28%). In 
all, 50% of the patients had intermittent and 50% had persistent 
asthma. Over three quarters (463/600; 77%) of patients had 
experienced allergic rhinitis symptoms in the past 12 months, 
of whom 96% had a previous diagnosis of allergic rhinitis. 
Asthmatics without allergic rhinitis symptoms had higher rates 
of visits to doctors, pharmacy visits, emergency department 
attendances, and hospitalisations for asthma than those with 
both conditions. Among subjects with asthma and allergic 
rhinitis, those taking nasal steroid (226/463; 49%) had lower 
rates of emergency department visits (13 vs 25%, P=0.002) and 
hospitalisations (7 vs 13%, P=0.045) for asthma than those who 
were not. 
 Conclusion Allergic rhinitis is a common co-morbid condition of asthma 
in this hospital clinic cohort. Treatment of allergic rhinitis with 
intra-nasal steroid was associated with less health care utilisation 
for asthma.
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Introduction
Allergic rhinitis (AR) is a common co-morbid condition associated with asthma. It is 
defined as inflammation of the lining of the nose and is characterised by nasal symptoms 
including anterior and/or posterior rhinorrhoea, sneezing, nasal blockage, and/or itching 
of the nose. These symptoms occur during 2 or more consecutive days, mostly for more 
than 1 hour, and are unrelated to upper respiratory tract infections.1 Asthma and AR are 
systemically linked by common and interrelated inflammatory processes of the upper 
and lower airways.2-4 The nose and the lower airway is a continuous passage and the 
nose plays a homeostatic role by conditioning the inhaled air. Local allergic reactions 
can trigger systemic inflammation that affects both the upper and the lower airway.3 A 
recent longitudinal study of 6461 subjects found that even in the absence of atopy, AR 
was a powerful predictor of adult-onset asthma.5 However, another study involving 1321 
subjects found that in AR patients referred to specialists, the features of AR, as described 
by the Allergic Rhinitis and its Impact on Asthma (ARIA) classification, did not predict the 
presence of asthma reliably.6
 Previous studies showed that over 80% of the asthmatics have AR, whereas 10 to 
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the QMH and PYNEH recruited 100 consecutive 
subjects each. All the subjects at PWH had pre- and 
post-bronchodilator spirometry, while the first 40 
and 20 subjects at QMH and UCH, respectively had 
spirometry performed on the day of the questionnaire 
survey. Patients were asked not to use any β-agonist 
for 6 hours prior to visiting to the clinic. Spirometry 
pre- and post-bronchodilator (after 400 mg albuterol 
given by metered dose inhaler with spacer) was 
performed according to the American Thoracic 
Society (ATS) and European Thoracic Society (ERS) 
standards14,15 using the Vitalograph (Buckingham, UK) 
spirometer. The updated predicted spirometry values 
for Hong Kong Chinese subjects were adopted.16 
Subjects with a history of chronic obstructive lung 
disease, bronchiectasis, or lung resection were 
excluded from this study.
 Both the doctor and the patient were asked to 
fill in separate questionnaires. The questionnaires 
were derived from well-validated questionnaires 
from the ISAAC.17 The ‘doctor’ questionnaire 
contained items on demographics of the subjects, 
their smoking history, age of onset of asthma, asthma 
severity evaluation (according to the Global Initiative 
of Asthma [GINA] 2005 guideline18) with day and night 
symptoms, use of rescue bronchodilator, and lung 
	 目的	 評估香港成人哮喘患者的過敏性鼻炎現患率，並將其
並存病症與沒有患過敏性鼻炎的成人哮喘患者作比
較。
	 設計	 橫斷面研究。
	 安排	 香港四家主要公立醫院的呼吸系統診所。
	 患者	 2007年3月至5月期間招募的600名成人哮喘患者。 
	主要結果測量	 醫生和患者分別完成評估症狀、治療和醫療保健運用
的問卷調查，及後收集部分患者的肺活量計數據。
	 結果	 267名男性和333名女性患者中，收集其中251名的
肺活量計數據。使用肺活量計的患者其支氣管擴張
劑使用前的一秒內用力呼氣量的中位數是88%（標準
差，28%）。總括而言，50%患有間歇性哮喘，50%
則有持續性哮喘。超過四分之三（463/600；77%）
的患者在過去12個月曾出現過敏性鼻炎症狀，當中
96%曾確診過敏性鼻炎。沒有過敏性鼻炎症狀的哮喘
患者無論因哮喘而求診、往藥房配藥、看急症和入院
的頻率都較有過敏性鼻炎症狀的哮喘患者為高。同
時有過敏性鼻炎症狀和哮喘的患者，使用鼻類固醇
（226/463；49%）的看急症（13比25%，P=0.002）
和入院（7比13%，P=0.045）頻率也較沒有使用者為
低。
	 結論	 根據上述患者組別的數據結果，過敏性鼻炎是哮喘的
併發病症。利用鼻腔用類固醇治療過敏性鼻炎，有助
減輕與哮喘有關的醫療保健服務負擔。
成人哮喘患者的過敏性鼻炎現患率和相關
病症：多中心研究
40% of AR patients have concomitant asthma.7 There 
are data suggesting that patients with asthma and AR 
endured increased morbidity and were more likely 
to use health care facilities than those with asthma 
alone.8-10 In a 52-week multicentre study carried 
out in a western population, the presence of self-
reported concomitant AR in patients with asthma 
was associated with a higher rate of asthma attacks 
and emergency room visits in comparison to those 
without AR.8 Another study in the United Kingdom 
reported that adults with asthma and documented 
concomitant AR experienced more asthma-related 
general practitioner visits and hospitalisations, and 
incurred higher asthma drug cost than those having 
asthma alone.9
 A recent survey explored the impact of AR co-
morbidity in patients with asthma in four countries 
in the Asia-Pacific region (China, Singapore, South 
Korea, and Taiwan) and four countries in Europe 
(France, Germany, Italy, and United Kingdom).11 
The survey found that most patients (73%) had pre-
existing symptoms of AR when their asthma was first 
diagnosed. Data from the Phase III International Study 
of Asthma and Allergies in Childhood (ISAAC) have 
shown that the prevalence of rhino-conjunctivitis 
among the 13–14-year-old subjects were 10% and 
23% in China and Hong Kong, respectively.12 In Hong 
Kong, between 1995 and 2001, the prevalence of AR 
among school children aged 6 to 7 years has been 
reported to have increased, whereas there was no 
significant change in asthma prevalence.13 Limited 
information, however, is available concerning the 
prevalence of rhinitis among adults with asthma in 
Hong Kong.
 This study aimed to assess the prevalence 
of rhinitis in adults with asthma in Hong Kong. In 
addition, we assess whether patients with asthma 
having concomitant AR endure higher morbidity 
than asthma patients without AR.
Methods
This was a cross-sectional study involving the 
respiratory clinics of four major public hospitals in 
Hong Kong (the Pamela Youde Nethersole Eastern 
Hospital [PYNEH], the Prince of Wales Hospital 
[PWH], the Queen Mary Hospital [QMH], and the 
United Christian Hospital [UCH]). Subjects aged 
18 to 80 years were recruited from March to May in 
2007. All subjects had a diagnosis of asthma for at 
least 1 year based on symptoms (wheeze, shortness 
of breath, cough, or chest tightness), together with 
lung function measurements showing significant 
reversibility to bronchodilator (increase of ≥12% [and 
200 mL] in 1-second forced expiratory volume after 
400 µg albuterol delivered by a metered dose inhaler 
with a spacer). The PWH and UCH each recruited 
200 consecutive patients from their clinics, whereas 
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function (spirometry or peak expiratory flow rate if 
available), and questions on AR (using the severity 
classification according to the ARIA guideline7). 
The subjects would be regarded as positive for 
AR if they had any symptoms such as sneezing, 
or runny, blocked or itchy nose within the last 12 
months unrelated to upper respiratory infection. 
The AR subjects were diagnosed with intermittent or 
persistent types based on the self-reported duration 
of symptoms. Intermittent AR was defined as a report 
of nasal symptoms lasting less than 4 days/week or 
less than 4 weeks in the past 12 months. Persistent 
AR was defined as nasal symptoms lasting more than 
4 days/week and more than 4 weeks in the past 12 
months.7 The drug treatment for both asthma and 
AR was also recorded by the doctor. Concerning the 
questionnaire to patients, it contained information 
on the health care utilisation by the patient in the 
previous 12 months for asthma and for AR. The study 
was approved by the respective ethics committees of 
the four hospitals involved.
 Data were analysed by the Statistical Package 
for the Social Sciences (Windows version 13.0; SPSS 
Inc, Chicago [IL], US). Results were expressed as 
proportions or means and standard deviations (SDs). 
The t test was used for comparisons of continuous 
data and the χ2 test for discrete data. These were 
applied to the analysis of baseline characteristics, 
health care utilisation of the asthma subjects with or 
without AR, and the morbidity of the patients with AR 
on different kinds of treatment for the AR. Multiple 
logistic regression analysis was used to assess the 
health care utilisation patterns of patients with 
asthma and AR in comparison to those of subjects 
with asthma but without AR, with adjustment of 
the age, smoking history, and asthma severity. The 
* AR denotes allergic rhinitis, FEV1 1-second forced expiratory volume, GINA Global Initiative of Asthma, ICS inhaled corticosteroid, and LABA inhaled long-acting 
β2 agonist
† Data are presented as No. (%) or mean ± standard deviation; because of rounding, not all percentages total 100
‡ Comparison between the asthma subjects with and without AR symptoms
TABLE 1. Demographic data of the asthma subjects
Demographics* Data† P value‡
All subjects (n=600) Subjects with AR 
symptoms (n=463)
Subjects without 
AR symptoms 
(n=137)
Age (years) 47 ± 15 44 ± 15 56 ± 14 <0.001
Sex 0.07
Male 267 (45) 197 (43) 70 (51)
Female 333 (56) 266 (57) 67 (49)
Body mass index (kg/m2) 24 ± 5 24 ± 5 25 ± 6 0.098
Age of onset of asthma (years) 25 ± 19 22 ± 18 35 ± 20 <0001
Duration of asthma (years) 23 ± 15 23 ± 15 22 ± 17 0.20
Smoking 0.03
Never smoker 455 (76) 362 (78) 93 (68)
Past smoker 106 (18) 72 (16) 34 (25)
Current smoker 39 (7) 29 (6) 10 (7)
Asthma severity by GINA guideline
Intermittent 297 (50) 241 (52) 56 (41) 0.02
Mild/moderate/severe persistent 303 (51) 222 (48) 81 (59)
Lung function test (sub-group of n=251) (n=204) (n=47)
Pre-bronchodilator FEV1 predicted (%) 88 ± 28 88 ± 20 86 ± 51 0.76
Post-bronchodilator FEV1 predicted (%) 95 ± 23 95 ± 18 94 ± 36 0.80
Asthma treatments
As-needed bronchodilator only 9 (2) 8 (2) 2 (1) 0.75
ICS (with and without LABA) 581 (97) 448 (97) 133 (97) 0.85
ICS with LABA 362 (60) 267 (58) 95 (69) 0.01
Theophylline 120 (20) 84 (18) 36 (26) 0.04
Leukotriene modifier 66 (11) 49 (11) 17 (12) 0.55
Long-acting oral β2 agonist 21 (4) 13 (3) 8 (6) 0.09
Oral steroid 21 (4) 12 (3) 9 (7) 0.03
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results were presented as odds ratios (ORs) and 95% 
confidence intervals (CIs). P values of less than 0.05 
were considered statistically significant.
Results
This study recruited 600 subjects (267 males, 45%), 
whose demographic data are shown in Table 1. Pre- 
and post-bronchodilator spirometry was performed 
in a subgroup (n=251, 42%) from the PWH (n=194), 
QMH (n=39) and UCH (n=18) on the same day of the 
questionnaire survey. Among these patients, 6, 1, and 
2 respectively were unable to perform reproducible 
spirometry according to the ATS/ERS standard.14,15 
Patients who had spirometry assessment did not differ 
from those not undergoing such assessment with 
respect to age, gender, asthma severity, and asthma 
medications prescribed (including inhaled steroids, 
inhaled long-acting β2 agonists, and leukotriene 
modifiers). However, the percentage with AR (81% vs 
74%; P=0.04) and percentage of never smokers (84% 
vs 70%; P<0.001) among those undergoing spirometry 
was higher (Table 2). For current and ex-smokers, the 
median (interquartile range) pack-years of smoking 
were 10 (4-20) and 7 (1.5-20), respectively.
 All the patients had a clinical diagnosis of asthma 
based on the GINA 2005 guideline18 that classified 
the subjects into intermittent, mild/moderate/severe 
persistent asthma according to their symptoms 
and lung function results (if available). Among the 
subjects, 50% and 13%/24%/15% had intermittent 
and mild/moderate/severe persistent asthma, 
respectively. Overall, 463 (77%) of the subjects had 
AR symptoms (sneezing or runny or blocked nose 
when not having a cold or flu) in the past 12 months 
and among these, 445 (96%) had a previous diagnosis 
of AR. The mean (SD) duration of the diagnosis of AR 
was 23 (18) years; in 149 (32%) AR was seasonal and 
in 314 (68%) it was perennial rhinitis with seasonal 
exacerbations. The rates of the different severities of 
the AR symptoms according to the ARIA guideline7 
and the treatment they received are shown in Table 
3. More subjects had intermittent AR (62%) than 
persistent AR (38%). Among subjects with persistent 
AR symptoms, more than 50% were in receipt of nasal 
glucocorticosteroid, and less than 5% were taking a 
leukotriene modifier.
 Health care utilisation data pertaining to these 
asthmatic patients with and without AR symptoms 
are shown in the Figure. Asthmatics without AR 
had higher rates of unscheduled visits to doctors, 
pharmacies, and emergency departments as well 
as hospitalisation for asthma symptoms than those 
with AR symptoms. Subjects with both asthma and 
AR symptoms were more likely than the rest to visit 
doctors and pharmacy stores and take sick leave for 
nasal symptoms. In subjects with asthma and AR 
* AR denotes allergic rhinitis, GINA Global Initiative of Asthma, ICS inhaled corticosteroid, 
and LABA inhaled long-acting β2 agonist
† Data are presented as No. (%) or mean ± standard deviation
TABLE 2. Comparison of the demographics of subjects with and without spirometry 
results
Demographics* Data† P value
With 
spirometry 
(n=251)
Without 
spirometry 
(n=349)
Age (years) 46 ± 14 47 ± 17 0.68
Sex 0.15
Male 103 (41) 164 (47)
Female 148 (59) 185 (53)
Symptoms of AR 204 (81) 259 (74) 0.04
Smoking
Never smoker 212 (84) 243 (70) <0.001
Past smoker 29 (12) 77 (22)
Current smoker 10 (4) 29 (8)
Asthma severity by GINA guideline
Intermittent 136 (54) 161 (46) 0.05
Persistent 115 (46) 188 (54)
Asthma medications
ICS with or without LABA 242 (96) 339 (97) 0.62
ICS + LABA 153 (61) 209 (60) 0.79
Leukotriene modifier 25 (10) 41 (12) 0.49
* ARIA denotes Allergic Rhinitis and its Impact on Asthma, and H1 histamine
TABLE 3.  Treatment of the different severities of allergic rhinitis (AR)*
Treatment of AR AR severity according to the ARIA guideline,7 No. (%) All subjects with 
AR (n=463), No. (%)
Intermittent mild 
(n=237)
Intermittent 
moderate-severe 
(n=51)
Persistent mild 
(n=91)
Persistent 
moderate-severe 
(n=84) 
Oral H1 blocker 50 (21) 13 (25) 29 (32) 44 (52) 136 (29)
Nasal H1 blocker 0 0 0 0 0
Oral decongestant 6 (3) 1 (2) 2 (2) 1 (1) 10 (2)
Nasal decongestant 0 0 1 (1) 1 (1) 2 (0.4)
Leukotriene modifier 6 (3) 1 (2) 1 (1) 3 (4) 11 (2)
Nasal glucocorticosteroid 100 (42) 21 (41) 49 (54) 56 (67) 226 (49)
		#		Ko	et	al	#
358	 Hong	Kong	Med	J		Vol	16	No	5	#	October	2010	#		www.hkmj.org
symptoms, those on nasal steroids had lower rates 
of visits to emergency departments (13% vs 24%; 
P=0.002) and hospitalisation (7% vs 13%; P=0.045) 
for asthma compared with those not using nasal 
steroids. The relationship between the treatment 
for AR and the health care utilisation in patients with 
both asthma and AR is shown in Table 4.
 Multiple logistic regression showed that after 
adjustment for age, smoking, and asthma severity, 
those with asthma and AR had lower likelihood of 
unscheduled visits to doctors for asthma symptoms 
(OR=0.62; 95% CI, 0.41-0.96; P=0.030) and a higher 
likelihood of visiting pharmacies for nasal symptoms 
(OR=3.47; 95% CI, 1.48-8.12; P=0.004) than subjects 
with asthma without AR (Table 5). There were no 
differences between the two groups in terms of 
visits to pharmacies for asthma symptoms, visits to 
emergency departments, hospitalisation for asthma, 
and the taking of sick leave for asthma and nasal 
symptoms.
Discussion
In this multicentre clinic cohort of asthma patients 
FIG. Morbidity of the asthma subjects with and without allergic rhinitis symptoms
AR denotes allergic rhinitis and ER emergency room; P value comparing the asthma subjects with AR and those without AR
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TABLE 4. Morbidity of patients with asthma and rhinitis stratified by the treatment of rhinitis
Morbidity No. (%)
On oral anti-histamine On nasal glucocorticosteroid
Yes (n=136) No (n=327) P value Yes (n=226) No (n=237) P value
Extra doctor visit due to asthma symptoms 66 (49) 100 (31) <0.001 74 (33) 92 (39) 0.173
Visit pharmacy due to asthma symptoms 10 (7) 23 (7) 0.90 14 (6) 19 (8) 0.446
Visit emergency room due to asthma symptoms 34 (25) 54 (17) 0.03 30 (13) 58 (24) 0.002
Hospitalisation due to asthma 14 (10) 32 (10) 0.87 16 (7) 30 (13) 0.045
Visit pharmacy due to nose symptoms 25 (18) 59 (18) 0.93 42 (19) 42 (18) 0.810
Take any sick leave for asthma symptoms 27 (20) 58 (18) 0.59 39 (17) 46 (19) 0.550
Take any sick leave for nose symptoms 14 (10) 27 (8) 0.48 27 (12) 14 (6) 0.022
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in Hong Kong, AR was a very common co-morbid 
illness, as shown by the fact that 77% of them had 
symptoms of AR in the previous 12 months and 
among these, 96% had a previous diagnosis of AR. 
Interestingly, patients with asthma and concomitant 
AR tended to be younger, had more intermittent than 
persistent asthma compared with asthmatics without 
AR. In patients with asthma and concomitant AR, nasal 
steroid treatment was associated with lower rates of 
visits to emergency departments and hospitalisation 
for asthma symptoms.
 Previous studies suggested that AR was 
frequently underdiagnosed. In a study with 
investigator-confirmed AR, 45% of patients had not 
reported a previous diagnosis by physicians.19 Most 
individuals with AR self-medicate using over-the-
counter antihistamines however.20 Available data 
on the prevalence of AR among Chinese adult are 
limited. A recent study found that the self-reported 
prevalence of AR in 11 cities across mainland China 
had wide variations, ranging from less than 10% to 
more than 20%.21 Another study from rural China 
involving 10 009 asthmatic subjects reported a 
prevalence rate of 6.2%.22 In our cohort, we observed 
that over 95% of the subjects with AR symptoms in 
the past 12 months had a diagnosis of AR. A hospital-
based study as opposed to a community study 
could explain this variation. Physicians working in 
respiratory clinics are more likely to explore nasal 
symptoms when managing their asthma patients than 
general practitioners who look after patients with a 
wide variety of medical problems. Even though the 
majority of patients had physician-diagnosed AR 
among those with AR symptoms, only about 50% and 
30% were treated with nasal steroids and oral anti-
histamine therapy, respectively (even fewer took a 
leukotriene modifier). These findings suggest under-
treatment of the condition.
 Most previous studies have suggested that 
AR increases the morbidity of asthma.8-10 One 
reported that adult asthmatics with concomitant 
AR consumed more asthma-related health care 
resources, in terms of general practitioner visits, 
hospitalisations, and prescription medication costs 
than did patients with asthma alone. Such results 
were consistent across different levels of asthma 
severity as assessed indirectly by analyses based on 
the intensity of asthma drug use.9 A similar pattern 
of health resources use was observed in children in a 
companion study based on the same general practice 
database.23 Another study found that presence of 
self-reported concomitant AR in patients with asthma 
resulted in higher rates of asthma attacks and more 
emergency room visits, but not on hospitalisations 
and unscheduled visits to doctors, compared 
with asthmatics with no AR, despite having milder 
and slightly better controlled asthma at baseline.8 
However, the enhanced effect of concomitant AR 
on the morbidity of asthma was not observed in the 
current study on adults. A previous study found that 
asthma severity among atopic subjects was less in 
persons with nasal symptoms than those without, 
whereas in non-atopic asthmatics the converse was 
true.24 As tests for atopy were not performed in the 
current study, we are not sure if atopic status might 
explain the milder asthma in our cohort with AR. After 
adjustment for age, smoking and asthma severity, 
patients with asthma and AR nevertheless had a lower 
rate of extra visits to doctors for asthma symptoms 
than those with asthma alone (Table 5). This suggests 
that the above-mentioned factors could not be the 
sole factors responsible for the higher morbidity in 
the asthma patients without concomitant AR.
 In the current study, about half of the subjects 
were treated with nasal steroids. Among patients 
with both AR and asthma, treatment of AR with 
nasal steroids was associated with fewer emergency 
department visits and hospitalisations for asthma 
than in those not using nasal steroids. There is 
presently a paucity of evidence to suggest that 
treating co-morbid AR confers better asthma-related 
outcomes in addition to any obvious benefits with 
regard to AR symptoms.4 Data as to whether intranasal 
steroids decrease bronchial hyperresponsiveness in 
lower airways are conflicting.25,26 One study showed 
* Logistic model with adjustment of age, smoking, and asthma severity
TABLE 5. Logistic regression analysis for morbidity of subjects with asthma and rhinitis compared with asthma alone (subjects with asthma and AR are 
taken as the reference in the logistic regression model)
Morbidity Crude odds ratio 
(95% confidence interval)
Crude  
P value
Adjusted odds ratio  
(95% confidence interval)*
Adjusted  
P value
Extra doctor visit due to asthma symptoms 0.54 (0.36-0.79) 0.001 0.62 (0.41-0.96) 0.030
Visit pharmacy due to asthma symptoms 0.54 (0.29-1.01) 0.052 0.52 (0.26-1.03) 0.060
Visit emergency room due to asthma symptoms 0.44 (0.29-0.66) <0.001 0.78 (0.39-1.55) 0.477
Hospitalisation due to asthma 0.32 (0.20-0.53) <0.001 0.88 (0.41-1.89) 0.745
Visit pharmacy due to nose symptoms 4.12 (1.86-9.13) <0.001 3.47 (1.48-8.12) 0.004
Take any sick leave for asthma symptoms 1.12 (0.67-1.85) 0.067 0.57 (0.30-1.08) 0.082
Take any sick leave for nose symptoms 4.34 (1.32-14.24) 0.015 2.46 (0.68-8.90) 0.169
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that they did not improve asthma symptoms, but 
bronchial responsiveness were not measured.27 A 
retrospective cohort study involving almost 5000 
American patients aged 12 to 60 years with co-morbid 
asthma and AR reported that in those receiving 
treatment for AR, three quarters experienced about 
half as many asthma-related events (hospitalisation 
or emergency department visits) than those not 
receiving such therapy.28 Similarly, in an Australian-
managed care population of 14 000 asthmatic patients 
aged 5 years or older, treatment of AR with intranasal 
corticosteroids substantially reduced the risk of 
emergency department visits for asthma.29 A nested 
case-control study on a United States–managed care 
population found that in patients aged 6 years or 
older with concomitant asthma and AR, treatment 
with nasal corticosteroids or second-generation 
anti-histamines was associated with a lower risk 
of asthma-related emergency room treatments 
and hospitalisations.30 Treatment of AR with intra-
nasal steroids was associated with less health care 
utilisation for asthma in the current study subjects. 
Further studies are nevertheless needed to assess 
whether intranasal steroids decrease the morbidity 
from asthma in patients who also have AR.
 It appears that subjects with asthma and 
concomitant AR who took anti-histamine had higher 
rates of additional doctor and emergency room visits 
for asthma. Whether poorly controlled AR symptoms, 
with its associated need for more symptomatic relief 
from anti-histamine, leads to more asthma symptoms 
and thus asthma-related health care utilisation 
among our patients is uncertain. As only a few 
subjects in our study were treated with a leukotriene 
modifier (<5%), it was not possible to assess its role 
in influencing asthma outcomes. In the post-hoc 
analysis of a randomised controlled trial comparing 
the addition of montelukast against doubling the 
dose of inhaled corticosteroid (ICS) for 12 weeks 
in subjects whose asthma was uncontrolled on the 
standard doses,31 for asthma patients with co-morbid 
AR, those prescribed montelukast enjoyed better 
lung function than those treated with doubled doses 
of ICS.32 This finding implies an additional benefit 
to asthma control from a systemic agent that is 
able to treat both AR and asthma.32 Previous studies 
suggested patients rated their AR disease as more 
severe than their physicians.33 Conceivably, under-
treatment of AR could be due to under-estimation 
of AR disease severity by physicians.4 Presence of AR 
was also found to be associated with poor quality 
of life.34,35 Studies to assess whether our asthmatic 
subjects might demand less health care utilisation 
and enjoyed improved quality of life upon treatment 
of their rhinitis (eg with intranasal steroid, leukotriene 
modifier, anti-histamines) would be of interest.
 The merit of the current study was that it 
entailed a cross-sectional survey completed by both 
patients and physicians, in contrast to previous 
studies using large health care databases.9,10,23 
In addition, a subgroup of subjects in this study 
underwent lung function assessment, whereas most 
of the previous studies using databases omitted 
spirometry. The limitations of this study included 
its relatively small sample size and atopic status not 
being tested (by skin test or specific immunoglobulin 
E level determinations). In addition, the asthma 
classification used in the current study was based 
on ‘severity’ not ‘control’ as suggested in the latest 
GINA guideline.36 Furthermore, drug compliance 
of the subjects was not assessed. Our patients 
probably had more severe asthma than those in the 
general population as they were being followed up 
at tertiary medical centres. Thus, the observations 
from this study might not be applicable to the broad 
population of asthma subjects in the community.
 In conclusion, AR is a very common co-morbid 
condition associated with asthma in this hospital 
clinic cohort. Further studies to determine what 
treatment options can offer benefits to patients with 
asthma and concomitant AR are warranted.
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